Cargando…
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
AIMS: ARIADNE aimed to assess the association between effects of sacubitril/valsartan and no sacubitril/valsartan treatment and clinical characteristics, functional capacity, and clinical outcomes (cause‐specific mortality and hospitalizations) in outpatients with heart failure (HF) with reduced eje...
Autores principales: | Maggioni, Aldo P., Clark, Andrew L., Barrios, Vivencio, Damy, Thibaud, Drozdz, Jaroslaw, Fonseca, Candida, Lund, Lars H., Kalus, Stefanie, Ferber, Philippe C., Hussain, Rizwan I., Koch, Cornelia, Zeymer, Uwe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773755/ https://www.ncbi.nlm.nih.gov/pubmed/36106548 http://dx.doi.org/10.1002/ehf2.14014 |
Ejemplares similares
-
Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry
por: Zeymer, Uwe, et al.
Publicado: (2020) -
Switching to sacubitril/valsartan or adding aldosterone antagonist: which first?
por: Escobar, Carlos, et al.
Publicado: (2019) -
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M, et al.
Publicado: (2021) -
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019) -
Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
por: Landolfo, Matteo, et al.
Publicado: (2020)